Revolution Medicines Inc
NASDAQ:RVMD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.13
80.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Revolution Medicines Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
15.3B USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.8B USD |
4%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.3B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
154.2B USD |
28%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.9B USD |
31%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.1B AUD |
19%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
53.7B USD |
1%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.3B EUR |
43%
|
Revolution Medicines Inc
Glance View
Revolution Medicines Inc. is a clinical-stage biotechnology company dedicated to reinventing cancer therapy through the development of targeted therapies that specifically inhibit proteins known as RAS. Recognized as one of the most challenging targets in cancer treatment, RAS mutations are implicated in a majority of solid tumors, making breakthrough innovations in this area essential. The company’s lead product candidate, RMC-6236, aims to offer a novel approach for patients with advanced cancers driven by specific mutations. By leveraging a proprietary drug discovery platform, Revolution Medicines is distinctly positioned to advance its pipeline of drug candidates through clinical trials, focusing on delivering precision strategies in oncology that promise transformative outcomes. As a forward-thinking entity in the biotech space, Revolution Medicines is not just about addressing current market needs but is also strategically crafting partnerships and collaborations to bolster its research and development capabilities. The company envisions a future in which its targeted therapies can significantly improve survival rates and quality of life for cancer patients. Investors are drawn to Revolution Medicines not only for its pioneering science but also for its robust clinical development strategy and the potential for substantial market impact as it tackles one of the most prevalent health challenges in society today. With a focus on delivering shareholder value while addressing significant unmet medical needs, Revolution Medicines is positioning itself as a leader in the quest for effective cancer treatments.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Revolution Medicines Inc's most recent financial statements, the company has Net Margin of 0%.